PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas

INTRODUCTION: Dopamine-agonist (DA) resistant prolactinomas are characterized by failure to achieve normal prolactin levels or reduce tumor size by at least 50% on maximal conventional DA dosages. This occurs in about 10% of patients on cabergoline and is more common in larger macroadenomas, and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Levine, Alice, Bass, Ilana, Alba, Eva, Umphlett, Melissa, Shuman, William, Milgrim, Emily, Milgrim, Lucas, Bederson, Joshua, Post, Kalmon, Shrivastava, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625567/
http://dx.doi.org/10.1210/jendso/bvac150.1139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625567/
http://dx.doi.org/10.1210/jendso/bvac150.1139

Ejemplares similares